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Abstract 
 
In the past years many (randomised) trials have been performed comparing the treatment strategies 
for lupus nephritis. In 2012 these data were incorporated in six different guidelines for treating lupus 
nephritis. These guidelines are European, American and internationally based, with one separate 
guideline for children. They offer information on different aspects of the management of lupus 
nephritis including induction and maintenance treatment of the different histological classes, 
adjunctive treatment, monitoring of the patient, definitions of response and relapse, indications for 
(repeat) renal biopsy, and additional challenges such as the presence of vascular complications, the 
pregnant SLE patient, treatment in children and adolescents, and considerations about end-stage 
renal disease and transplantation. In this review we summarize the guidelines, determine the 
common ground between them, highlight the differences and discuss recent literature. 
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Introduction 
Lupus nephritis (LN) is associated with poor survival [1, 2] and considerable morbidity, particularly for 
patients who develop end-stage renal disease (ESRD) and require renal replacement therapy. The 
development of renal involvement within the course of disease ranges from approximately 20 to 60 
per cent of systemic lupus erythematosus (SLE) patients [3] with the highest risk of renal disease and 
renal failure in young black women [4, 5]. Therapeutic possibilities have expanded from the solitary 
use of corticosteroids to the addition of a wide range of immunosuppressive drugs and other 
supportive treatment. Many trials have been conducted in the past 40 years leading to the 
publication of six guidelines in 2012 on the management of LN (Table 1) [6-11]. These guidelines are 
American and European based, with separate guidelines from Spain and the Netherlands, with the 
addition of the KDIGO (Kidney Disease Improving Global Outcomes) guideline that is considered to be 
international. All guidelines were developed on the basis of extensive literature searches and 
(consensus) meetings. Furthermore, each guideline indicated the level of evidence or strength of a 
statement/recommendation, or both, for all topics (Table S3). All guidelines were published in the 
same year and based on the same body of evidence and their main statements are congruent. 
However, there are also notable differences between them. The aim of this review is to compare the 
recent guidelines, outline a common view and highlight the differences, in particular in relation to 
indications for (repeat) renal biopsy, induction and maintenance treatment of the different classes, 
adjunctive treatment, monitoring of the patient, definitions of response and relapse, and additional 
circumstances such as the presence of vascular complications, the pregnant SLE patient, treatment in 
children and adolescents, and considerations about end-stage renal disease (ESRD) and 
transplantation (Tables 2, 3, S1 and S2). We will also discuss recent literature and how to proceed 
further to increase the level of evidence based patient care.
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Renal biopsy 
All guidelines recommend a renal biopsy when there is a suspicion of renal involvement, because 
clinical and laboratory parameters cannot accurately predict the histological class. Early diagnosis 
and treatment have been shown to improve outcomes [12, 13]. The criteria for suspicion of renal 
involvement, however, differ. The common view is that an unexplained decrease in renal function, 
and proteinuria are indications for a renal biopsy. Also, an active urine sediment raises the level of 
suspicion of renal involvement and may be an additional argument for a renal biopsy. The GEAS 
(Spanish Society of Internal Medicine and Spanish Society of Nephrology) considers an active urine 
sediment alone a sufficient cause for biopsy. The required levels of proteinuria differ between the 
guidelines, but most use a urine protein creatinine ratio of 50 mg/mmol (equivalent to approximately 
0.5 g/24h) as a cut-off.  
The biopsy is classified according to the system proposed by the International Society of Nephrology/ 
Renal Pathology Society (ISN/RPS) in 2003 [14].  A minimum of 10 glomeruli is required in order to 
reasonably exclude focal disease and the biopsy should be examined by light microscopy, 
immunofluorescence and if possible, electron microscopy. Furthermore, data on activity and 
chronicity should be quantified (though activity and chronicity indices are not obligatory) and 
vascular and interstitial lesions described. The histological class plays a fundamental role in the 
ensuing therapeutic decision process.  
Although the evidence is sparse, in cases of worsening of disease, disease refractory to treatment or 
relapse, a repeat biopsy can be considered to determine activity and chronicity or detect other 
pathologies. Some also suggest taking a biopsy at the end of induction treatment in order to 
determine the histological response, as clinical parameters may underestimate (histological) 
response [15, 16]. However, this strategy has not been officially tested in a controlled study but 
repeat renal biopsy has been shown to have prognostic value [17-20].  
 
6 
 
Treatment class II 
There is little agreement among the guidelines on treatment of class II LN due to lack of evidence. 
Proteinuria should primarily be managed with renin-angiotensin-aldosterone system (RAAS) 
inhibitors. The role of immunosuppression, however, is less clear. The ACR (American College of 
Rheumatology) guideline states that class II LN generally does not require immunosuppressive 
treatment. The EULAR/ERA-EDTA (European League Against Rheumatism and European Renal 
Association-European Dialysis and Transplant Association), however, recommends low to moderate 
doses of oral glucocorticoids (0.25-0.5 mg/kg/d) alone or in combination with azathioprine (AZA, 1-2 
mg/kg/d), if necessary as a steroid sparing agent, in cases of proteinuria over 1 g/24 h, especially in 
the presence of glomerular haematuria. In the GEAS guideline steroids up to 0.5 mg/kg/d, if 
necessary with AZA or mycophenolate mofetil (MMF), for 6-12 months are suggested for class II 
nephritis with proteinuria (>1-2 g/24 h) and/or a deteriorated renal function that are not attributable 
to functional factors. The suggestions in the KDIGO guideline for the use of immunosuppressive 
therapy focuses on the presence/co-existence of podocytopathy (i.e. minimal change disease (MCD)) 
in a subset of patients with class II LN [21, 22] and KDIGO suggests treating such patients with 
nephrotic range proteinuria (>3 g/24 h) with corticosteroids or calcineurin inhibitors (CNIs) as for 
MCD, but this presentation was not discussed in the ACR guidelines.  
 
Induction and maintenance treatment class III/IV 
Over the past decade several randomised controlled trials (RCTs) have been conducted for class III 
and IV LN, both in the induction and maintenance phase. Consequently, the guidelines are uniform in 
their recommendations for induction treatment: intravenous cyclophosphamide (ivCYC) or MMF (2-3 
g total daily dose) in combination with oral glucocorticoids with or without three pulses of 
intravenous methylprednisolone (MP) at start of induction treatment. Although in general the use of 
both oral and intravenous glucocorticoids has been proven effective, evidence is scarce concerning 
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dose and duration, and recommendations are mainly based on expert opinion. In the guidelines, the 
initial dose of oral glucocorticoids varies from 0.5 to 1.0 mg/kg/d. Only one small RCT compared high 
(1mg/kg) and low (0.5 mg/kg) dose oral glucocorticoids (in a background of enteric coated 
mycophenolic acid). This study demonstrated an equal percentage (approximately 20%) of complete 
responses at 24 weeks, although non-inferiority was not proven. It did, however, show a decrease in 
infections in favour of the low dose group [23].  Furthermore, advice for tapering of glucocorticoids is 
usually fairly general, except for the guideline from the Dutch Working Party on SLE (DWP), which 
devised a schedule for tapering (Table S1). The use of pulse MP at induction is not always 
recommended and is reserved by some of the guidelines for more severe cases. However, there is 
some indication that the use of pulse MP combined with medium dose oral glucocorticoids may be as 
effective as high dose oral glucocorticoids in inducing remission, but with less toxicity [24]. MMF and 
ivCYC have similar efficacy and adverse event rates when used with glucocorticoids for remission 
induction, but MMF avoids adverse effects on fertility. For ivCYC both the low dose Eurolupus 
regimen (500 mg fortnightly for 3 months) and the higher dose NIH regimen (0.5-1 g/m2 monthly for 
6 months) can be used. However, the low dose is usually preferred for (European) Caucasians and 
sometimes only for milder cases because the original trials were mostly in this group of patients [25, 
26]. The ACCESS trial, communicated after publication of the guidelines, showed no benefit of 
abatacept as add-on to induction therapy. However, in a predominantly non-Caucasian study 
population comparable response rates to low dose ivCYC were observed to those previously 
reported, suggesting that low dose ivCYC may be as effective in non-Caucasians as in Caucasians [27], 
although further evidence will be required. Finally, MMF is sometimes preferred over ivCYC in 
patients from African or Hispanic descent, based on a ‘post-hoc’ subgroup analysis of the ALMS trial 
[28].  Some of the guidelines advise more aggressive therapy in patients with crescents in the biopsy 
specimen, as detailed in Table 2. The EULAR/ERA-EDTA and KDIGO guidelines also state that patients 
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should have active lesions (class III/IVA or class III/IVA/C) in order to be treated and should not have 
merely chronic lesions (class III/IVC). 
For severe LN, although not adequately defined, there is less evidence as these patients are often 
excluded from RCTs. However, a subgroup analysis of the ALMS trial in patients with a baseline 
estimated glomerular filtration rate (eGFR) <30 ml/min did not reveal a difference between ivCYC 
and MMF [29]. Unfortunately, numbers were small (32 in total) and there was no follow-up beyond 
the induction phase. Recently, Rovin et al. performed a systematic review using results extracted 
from clinical trials and drawn from expert opinion. Severe LN was arbitrarily defined by renal 
histology, resistance to therapy, or GFR at presentation. They showed that ivCYC and MMF are 
equally effective in inducing remission. For long-term follow-up (5 years), however, results from 
retrospective and observational studies suggest there may be a better preservation of renal function 
and fewer relapses with ivCYC [30]. Long-term follow-up data from RCTs, however, are lacking. 
In the maintenance phase of treatment, MMF (1-2 g/d) or AZA (1.5-2.5 mg/kg/d) are recommended 
by all guidelines, supported by low dose oral glucocorticoids. The EULAR/ERA-EDTA recommends 
MMF over AZA if there was a response to MMF at induction based on the combined results from the 
ALMS [31] and MAINTAIN trials [32]. The GEAS advises MMF over AZA, based on the results from the 
ALMS trial, although long-term effects of MMF are still lacking. Also, a recent meta-analysis of four 
trials (including MAINTAIN and ALMS) showed that there is no difference between MMF and AZA 
with respect to preventing relapse, progression to end-stage renal failure, death and doubling of 
serum creatinine [33]. Finally, with respect to duration of treatment, the guidelines differ: at least 3 
years (EULAR/ERA-EDTA) or at least 1 (KDIGO) or 2 (GEAS) years after (complete) remission. Due to 
the length of completed studies, there is no advice on the optimal duration of therapy beyond 3 
years. 
 
Induction and maintenance treatment class V 
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Evidence in support of immunosuppressive therapy in patients with pure class V LN is less robust. 
Most of the guidelines suggest initiating immunosuppressive treatment if there is nephrotic range 
proteinuria (>3 g/24 h). If proteinuria is subnephrotic, management with RAAS inhibitors is 
recommended to reduce the levels of protein excretion. The GEAS, on the other hand, advises 
immunosuppression irrespective of the level of proteinuria. There is also no consensus on which 
immunosuppressive therapy to initiate, although there is agreement that glucocorticoids should be 
included in the regimen. The EULAR/ERA-EDTA and ACR guidelines prefer the addition of MMF over 
other immunosuppressives (ivCYC, CNIs, AZA or rituximab), in contrast to the GEAS and KDIGO that 
do not state a preference for any of the aforementioned possibilities. The preference for MMF is 
mainly based on a combined retrospective analysis of class V LN patients of two RCTs demonstrating 
that MMF 2-3 g total daily dose plus daily prednisone for 6 months and ivCYC (0.5-1.0 mg/kg 
monthly) plus prednisone for 6 months resulted in similar improvement [34]. Unfortunately, due to 
the short follow-up of this study the long-term efficacy remains unknown. Another RCT compared 
prednisone (40 mg/m2 orally, tapered after 8 weeks to reach 10 mg/m2 by 12 months) alone on 
alternate days with the addition of either ivCYC (500-1000 mg/m2 every 2 months for 6 doses) or 
ciclosporin (5 mg/kg for 11 months). Results showed that the combination of prednisone with ivCYC 
or ciclosporin led to higher remission rates than prednisone alone, but relapse of nephrotic 
syndrome occurred significantly more often after completion of ciclosporin than after ivCYC [35]. As 
evidence is lacking on maintenance therapy in class V LN, it is suggested to treat according to 
maintenance regimens for class III/IV LN. The efficacy in idiopathic membranous glomerulopathy of 
tacrolimus, ciclosporin and rituximab also supports a therapeutic role for these agents in lupus 
membranous nephropathy [36-38].  
 
Monitoring 
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The guidelines differ in their approach but agree that patients with active nephritis should have a 
visit scheduled at least every month, particularly at induction, relapse and withdrawal of treatment. 
If there is no active nephritis every 3 to 6 months should suffice, although vigilance is required for 
prompt identification of disease relapse. At each visit body weight, blood pressure, serum creatinine 
(sCr), proteinuria, urinary sediment, complement levels, anti-dsDNA titres and according to some 
serum albumin and complete blood count, should be determined.  The ACR states that some of the 
aforementioned can be determined at larger intervals than others (blood pressure and urinalysis 
frequent; anti-dsDNA less frequent) and drafted a separate monitoring schedule for pregnancy (Table 
2 and S1). Recommendations in this area are all based on expert opinion.  Nevertheless, they can still 
serve as a guideline for the practicing physician. Also, a recommendation from the EULAR for 
monitoring patients with SLE was previously published [39]. 
 
Adjunctive treatment/treatment for comorbidities 
All guidelines recommend blood pressure control (target <130/80 mmHg), treatment of 
hyperlipidaemia with statins (target LDL < 100 mg/dl or 2.6 mmol/l) and treatment of proteinuria 
with RAAS inhibition.  The guidelines agree that all SLE patients should have a background of 
hydroxychloroquine (HCQ) unless contraindicated, since this is associated with less damage accrual 
[40]. There is a paucity of randomized evidence for the efficacy of HCQ on nephritis with only two 
retrospective studies supporting its use [41, 42]. Patients receiving HCQ have a risk of developing 
retinopathy and should therefore be screened by the ophthalmologist at baseline and yearly after 
five years. Patients with severe renal or hepatic disease are at higher risk for developing retinopathy, 
due to less clearance of the drug. In those patients reducing the dose should be considered to avoid 
toxicity. Other recommendations made by one or more of the guidelines are listed in Table 2 and 
involve treatment for side effects of drugs, prevention of clotting events and osteoporosis. There are 
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no clear recommendations from the guidelines on infective prophylaxis, such as for pneumocystis 
jirovecii pneumonia, or surveillance for other pathogens. 
 
Definitions of response and relapse 
When communicating about patients, either in trials or in clinical practice, it is essential that 
definitions for disease parameters such as partial and complete response and relapse or flare are the 
same. Previously, a very stringent European consensus statement was published on the terminology 
used in the management of lupus nephritis [43].  However, the choice of primary endpoint in clinical 
trials can also substantially influence the ability to detect therapeutic benefit, as demonstrated by 
Wofsy et al. [44]. The common ground and differences for the definitions of complete and partial 
response, relapse or flare, and refractory disease are outlined in Table 3 and S2. 
 
Treatment for refractory disease 
Although the definition for refractory disease is stated differently by the various guidelines, there is 
agreement on the treatment, although there is no clinical trial evidence for these approaches. It is 
generally advised to switch from MMF to ivCYC or vice versa if induction treatment fails. Some 
guidelines also state that again three pulses of intravenous MP should be administered. If this 
approach fails, the guidelines recommend other options: rituximab, as add-on or monotherapy, CNIs 
(also as add-on or monotherapy) or intravenous immunoglobulins. Of these, the main focus in 
literature has been on the use of rituximab, although with the LUNAR trial of rituximab as add-on to a 
steroid-MMF combination failing to meet its endpoint, it has not yet been proven effective in an RCT. 
Putative explanations for this failure include the possible overtreatment of relatively mild disease, 
short follow-up and underpowered study for the detection of an effect mainly consisting of partial 
responses [45]. Recently, a summary of the literature on the use of rituximab in refractory LN was 
published [46], which suggests that rituximab can induce a response in patients who did not achieve 
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remission on standard therapy. Also, Jónsdóttir and colleagues recently showed in a group of 25 
patients that add-on of rituximab to ivCYC and glucocorticoids resulted in both clinical and 
histological improvements in the majority of patients [47]. A recent, non-randomised, prospective 
study found promising results for a steroid sparing induction regimen [48] consisting of 2 doses of 
rituximab (1 g) and MP (500 mg) on day 1 and 15, and maintenance with MMF without oral steroids. 
A phase 3 open label multicentre investigator led RCT (RITUXILUP, NCT01773616) will start in 2015 
comparing this regimen to a ‘standard’ oral glucocorticoid/MMF regimen. 
Although RCTs are lacking, there is a growing body of evidence that CNIs may be useful in refractory 
disease, but one should be aware of the nephrotoxic effects, especially in patients with decreased 
renal function. These nephrotoxic effects (reviewed by Naesens et al. [49]) seem to be less for 
tacrolimus than for ciclosporin. Although not studied in refractory disease, in a recent Chinese 
randomized trial the combination of MMF (1.0 g/d) with tacrolimus (4 mg/d) was proven superior to 
ivCYC (0.5-1 g/m2 every 4 weeks for 6 doses) in achieving complete remission in patients with class 
IV, class V and class IV + V LN[50]. This could be due to a faster anti-proteinuric effect of tacrolimus 
and longer follow-up data are needed to determine the comparable efficacy of the two regimens. 
 
Pregnancy 
Pregnancy should not be planned until remission is reached and maintained for 6 months 
(EULAR/ERA-EDTA and GEAS). HCQ should be continued as multiple studies (reviewed by Ruiz-
Irastorza et al. [40]) have demonstrated its safety in pregnancy. RAAS inhibitors, MMF and 
cyclophosphamide are prohibited during pregnancy. As alternatives AZA, CNIs, methyldopa, labetalol 
or nifedipine can be prescribed, despite the classification of AZA (the same as MMF and ivCYC) as 
category D by the Food and Drug Administration (“positive evidence of human fetal risk based on 
adverse reaction data,  potential benefits may warrant use of the drug in pregnant women despite 
the potential risk”). AZA is considered safe during pregnancy as there is no evidence that AZA 
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increases the risk of congenital abnormalities (in contrast to MMF and CYC) and AZA cannot be 
metabolised to the active metabolite 6-mercaptopurine by the fetal liver [51, 52]. Low dose oral 
glucocorticoids (non-fluorinated) are acceptable. It is advised by the KDIGO not to taper 
glucocorticoids or AZA during pregnancy or for three months thereafter. Furthermore, low dose 
acetylsalicylic acid should be considered to reduce the risk of pre-eclampsia. Finally, all patients 
should be monitored closely, preferably by a multidisciplinary team that is used to managing such 
patients and is aware of the need to distinguish between a flare and pre-eclampsia, which may also 
co-exist. 
 
Vascular complications 
Anti-phospholipid syndrome-associated nephropathy (APSN) is a vascular nephropathy which can 
occur in SLE patients and may be associated with the presence of anti-phospholipid (aPL) antibodies. 
The EULAR/ERA-EDTA guideline takes the use of HCQ and/or antiplatelet or anticoagulant treatment 
into consideration, while the KDIGO and GEAS merely suggest treatment with anticoagulants (INR 2-
3). The ACR suggests treating thrombotic microangiopathy (TMA) primarily with plasma exchange. 
This area is further complicated by the inconsistent terminology used. TMA is a histological lesion, 
which is part of the APSN spectrum, but also has a clinical counterpart with systemic manifestations 
such as the presence of schistocytes in peripheral blood. Thrombotic thrombocytopenia (TTP) is a 
clinical syndrome associated with TMA in the renal biopsy, recommended to be treated promptly 
with plasma exchange by KDIGO (and other guidelines for idiopathic TTP, as TTP especially in SLE has 
a high mortality). In summary, recommendations differ because of inconsistent terminology and lack 
of evidence. Until this is solved, we recommend viewing TMA in the renal biopsy in the clinical 
context when determining treatment. If APSN is considered to be a small vessel manifestation of APS 
and laboratory criteria for the diagnosis of APS are met, it may be wise to treat it as such (with 
antiplatelet or anticoagulation therapy), at least until new evidence becomes available.  
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Management of ESRD and transplantation 
The modality of dialysis should be determined by patient choice. However, the risk of infection in 
increased with the use of immunosuppressive drugs. Hence, the GEAS suggests peritoneal dialysis 
should only be offered to patients with inactive disease on minimal immunosuppression. 
Haemodialysis is suitable for patients with active disease/more immune suppression. 
It is advised to determine the presence of aPL antibodies because this can increase the risk of 
vascular access thrombosis during dialysis and of vascular events in the transplant. Lupus activity 
should be absent or low for a period of 3-6 months (EULAR/ERA-EDTA) or 6-12 months (GEAS) to be 
eligible for transplantation. Although ESRD is often associated with remission of lupus activity, this is 
not universal and extra-renal lupus flares can still occur, patients should be managed accordingly.  
 
Children and adolescents 
The rate of developing LN during the course of disease is higher in children than in adults [53]. 
However, large trials comparing different treatment strategies in juvenile LN are lacking. The 
guidelines generally advise the same treatment strategies as for adults, except for the CARRA 
guideline, which is specifically aimed at children and adolescents. For dosages of the 
immunosuppressive drugs in children we refer to this guideline. In 2012, the first results from an RCT, 
a subgroup analysis of the ALMS trial, were published [54]. This subgroup analysis included 
adolescents aged 12 to 18 years. Although the numbers were small (24 patients in the induction 
phase and 16 in the maintenance phase) and therefore not sufficient to yield statistically significant 
results, it was noted that in general there was similar efficacy in adolescents and adults. Due to the 
small numbers the effect of ethnicity could not be determined.  
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Conclusion 
Although a substantial part of the management of LN is evidence-based, a significant part still rests 
on uncontrolled trials and expert opinion. Despite an increase in clinical trial activity during the last 
decade, there are areas where evidence is lacking, such as for the treatment of severe and refractory 
LN and of children. Furthermore, although the most important outcome is the long-term follow-up 
beyond 10 years due to the risk of end-stage renal failure at this time despite initial improvement in 
disease parameters, this data are scarce. Finally, it must be kept in mind that all guidelines are meant 
to assist physicians in the management of LN, but can never replace the insight of the experienced 
clinician in reaching a therapeutic strategy tailored to the individual patient.
16 
 
Conflict of interest statement or funding 
Suzanne Wilhelmus: none. 
Ingeborg M. Bajema is a consultant for Roche. 
Dimitrios T. Boumpas: none. 
George K. Bertsias: No conflict of interest. Supported by the FP7–2011-REGPOT-1 (TransPOT: 
‘Enhancing University of Crete Medical School Scientific Excellence and Translational Research 
Potential in Human Diseases’). 
Liz Lightstone:  Roche are providing drugs free of charge for the Rituxilup trial; honoraria /advisory 
boards/lecturing – GSK, Anthera Pharmaceuticals, MedImmune, Merck, Aspreva/Vifor Pharma, 
Biogen-Idec, UCB. 
 Caroline Gordon is a consultant on clinical trial design and has received honoraria for 
consultancy, participation in scientific advisory boards and lecturing for UCB, GSK and 
Bristol-Myers Squibb, and has received honoraria from Aspreva/Vifor Pharma, MedImmune, 
Genentech, Roche, and Merck Serono. 
David Jayne: Roche/Genentech are providing drugs for the RITAZAREM trial; honoraria/advisory 
boards/lecturing – GSK, Medimmune, Merck, Biogen-Idec, UCB 
Vladimir Tesar: lecturing for GSK and Roche, supported by the research project PRVOUK-P25/LF1/2. 
 
Also see separately filled out conflict of interest form.
17 
 
References 
1. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis 
Rheum 2006;54(8):2550-2557 
2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus 
erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 
1,000 patients. Medicine (Baltimore) 2003;82(5):299-308 
3. Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus 
nephritis: a retrospective analysis. Am J Med 2002;112(9):726-729 
4. Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and prevalence of 
systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis 
Rheumatol 2014;66(2):369-378 
5. Lim SS, Bayakly AR, Helmick CG, et al. The incidence and prevalence of systemic lupus 
erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis Rheumatol 2014;66(2):357-368 
6. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and 
European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) 
recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 
2012;71(11):1771-1782 
7. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for 
screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 
2012;64(6):797-808 
8. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. 
KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012;2:139-274 
9. Ruiz Irastorza G, Espinosa G, Frutos MA, et al. Diagnosis and treatment of lupus nephritis. 
Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of 
Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.). Nefrologia 2012;32 Suppl 1:1-35 
10. van Tellingen A, Voskuyl AE, Vervloet MG, et al. Dutch guidelines for diagnosis and therapy of 
proliferative lupus nephritis. Neth J Med 2012;70(4):199-207 
11. Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of 
newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care 
Res (Hoboken) 2012;64(3):375-383 
12. Wakasugi D, Gono T, Kawaguchi Y, et al. Frequency of class III and IV nephritis in systemic 
lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J 
Rheumatol 2012;39(1):79-85 
13. Christopher-Stine L, Siedner M, Lin J, et al. Renal biopsy in lupus patients with low levels of 
proteinuria. J Rheumatol 2007;34(2):332-335 
14. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in 
systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15(2):241-250 
15. Condon MB, Lightstone L, Cairns T, et al. Is rebiopsy required to identify complete remission 
in patients treated for lupus nephritis? J Am Soc Nephrol 2009;20:405A 
16. Gunnarsson I, Sundelin B, Jonsdottir T, et al. Histopathologic and clinical outcome of 
rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. 
Arthritis Rheum 2007;56(4):1263-1272 
17. Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclophosphamide delays the 
progression of chronic lesions more effectively than does treatment with azathioprine plus 
methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007;56(3):924-
937 
18. Hill GS, Delahousse M, Nochy D, et al. Predictive power of the second renal biopsy in lupus 
nephritis: significance of macrophages. Kidney Int 2001;59:304-316 
18 
 
19. Alsuwaida A, Husain S, Alghonaim M, et al. Strategy for second kidney biopsy in patients with 
lupus nephritis. Nephrol Dial Transplant 2012;27(4):1472-1478 
20. Pagni F, Galimberti S, Goffredo P, et al. The value of repeat biopsy in the management of 
lupus nephritis: an international multicentre study in a large cohort of patients. Nephrol Dial 
Transplant 2013;28(12):3014-3023 
21. Kraft SW, Schwartz MM, Korbet SM, et al. Glomerular podocytopathy in patients with 
systemic lupus erythematosus. J Am Soc Nephrol 2005;16(1):175-179 
22. Mok CC, Cheung TT, Lo WH. Minimal mesangial lupus nephritis: a systematic review. Scand J 
Rheumatol 2010;39(3):181-189 
23. Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in 
combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 
2011;20(14):1484-1493 
24. Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is 
enough? Autoimmun Rev 2014;13(2):206-214 
25. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus 
Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 
2010;69(1):61-64 
26. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: 
the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous 
cyclophosphamide. Arthritis Rheum 2002;46(8):2121-2131 
27. The ACCESS Trial Group. Treatment of Lupus Nephritis With Abatacept: The Abatacept and 
Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 2014;66(11):3096-
3104 
28. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus 
nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010;49(1):128-140 
29. Walsh M, Solomons N, Lisk L, et al. Mycophenolate mofetil or intravenous cyclophosphamide 
for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management 
Study. Am J Kidney Dis 2013;61(5):710-715 
30. Rovin BH, Parikh SV, Hebert LA, et al. Lupus nephritis: induction therapy in severe lupus 
nephritis - should MMF be considered the drug of choice? Clin J Am Soc Nephrol 2013;8(1):147-153 
31. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance 
therapy for lupus nephritis. N Engl J Med 2011;365(20):1886-1895 
32. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-
term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum 
Dis 2010;69(12):2083-2089 
33. Feng L, Deng J, Huo DM, et al. Mycophenolate mofetil versus azathioprine as maintenance 
therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton) 2013;18(2):104-110 
34. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous 
cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 
2010;77(2):152-160 
35. Austin HA, 3rd, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, 
cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 
2009;20(4):901-911 
36. Praga M, Barrio V, Juarez GF, et al. Tacrolimus monotherapy in membranous nephropathy: a 
randomized controlled trial. Kidney Int 2007;71(9):924-930 
37. Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive 
membranous nephropathy: a UK randomised controlled trial. Lancet 2013;381(9868):744-751 
38. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. 
J Am Soc Nephrol 2012;23(8):1416-1425 
19 
 
39. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations 
for monitoring patients with systemic lupus erythematosus in clinical practice and in observational 
studies. Ann Rheum Dis 2010;69(7):1269-1274 
40. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of 
antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69(1):20-28 
41. Barber CE, Geldenhuys L, Hanly JG. Sustained remission of lupus nephritis. Lupus 
2006;15(2):94-101 
42. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal 
remission within 12 months among patients treated with mycophenolate mofetil therapy for 
membranous lupus nephritis. Lupus 2006;15(6):366-370 
43. Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in 
the management of lupus glomerulonephritis. Lupus 2009;18(3):257-263 
44. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for 
use in lupus nephritis clinical trials. Arthritis Rheum 2013;65(6):1586-1591 
45. Lightstone L. The landscape after LUNAR: rituximab's crater-filled path. Arthritis Rheum 
2012;64(4):962-965 
46. Weidenbusch M, Rommele C, Schrottle A, et al. Beyond the LUNAR trial. Efficacy of rituximab 
in refractory lupus nephritis. Nephrol Dial Transplant 2013;28(1):106-111 
47. Jonsdottir T, Zickert A, Sundelin B, et al. Long-term follow-up in lupus nephritis patients 
treated with rituximab - clinical and histopathological response. Rheumatology (Oxford) 
2013;52(5):847-855 
48. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study 
to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil 
but no oral steroids. Ann Rheum Dis 2013;72(8):1280-1286 
49. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc 
Nephrol 2009;4(2):481-508 
50. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a 
randomized trial. Ann Intern Med 2015;162(1):18-26 
51. Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive 
drugs and reproduction. Arthritis Res Ther 2006;8(3):209 
52. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to 
azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007;79(10):696-701 
53. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-
onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011;20(13):1345-1355 
54. Sundel R, Solomons N, Lisk L. Efficacy of mycophenolate mofetil in adolescent patients with 
lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus 2012;21(13):1433-
1443 
55. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 
Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney 
Int Suppl 2012;2(5):337-414 
 
20 
 
 
From Date of publication Geography Population 
EULAR/ERA-EDTA : European 
League Against Rheumatism and 
European Renal Association–
European Dialysis and Transplant 
Association[6] 
July 2012 Europe Adults and children/adolescents 
 
ACR: American College of 
Rheumatology[7] 
June 2012 USA Adults, particularly those receiving 
care in the USA 
Includes interventions available in 
the USA as of February 2012 
KDIGO: Kidney Disease: Improving 
Global Outcomes 
Glomerulonephritis Work Group[8]  
May 2012 International Adults and children/adolescents 
GEAS: Systemic auto-immune 
disease group of the Spanish 
Society of Internal Medicine and 
Spanish Society of Nephology[9] 
March 2012 Spain Not specified 
DWP: Dutch Working Party on 
Systemic Lupus Erythematosus[10] 
March 2012 The Netherlands Not specified 
For proliferative LN only 
CARRA: Childhood Arthritis and 
Rheumatology Research 
Alliance[11] 
March 2012 North America Children/adolescents 
For proliferative LN only 
Consensus treatment plan, not a 
guideline 
Table 1. Guidelines that were compared 
Abbreviations: LN=lupus nephritis; USA=United States of America.
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 Common view Differences 
Indication for 
renal biopsy 
Inexplicable (persistent) decrease  in renal 
function 
Reproducible proteinuria (required levels: 
different) 
Active sediment raises level of suspicion for LN 
and may be an additional argument for a renal 
biopsy 
Proteinuria: 
 most: isolated proteinuria ≥0.5 g/24 h 
 ACR: isolated proteinuria ≥1.0 g/24 h or ≥0.5 
g/24 h and haematuria (5 RBCs/HPF) or cellular 
casts 
Active sediment: sufficient to warrant biopsy in 
GEAS, others consider a biopsy, sometimes when in 
combination with low levels of proteinuria 
Biopsy 
evaluation 
According to ISN/RPS 2003 classification system 
for LN 
Examine by light microscopy, immuno-
fluorescence and if possible electron microscopy 
Quantify data on activity and chronicity and 
describe vascular and interstitial lesions 
- 
Indication for 
repeat biopsy 
Consider in case of: 
 Worsening of disease or disease refractory 
to treatment  
 Relapse, in order to demonstrate change or 
progression in histological class, change in 
activity and chronicity (index) or other 
pathologies 
- 
Treatment 
class II 
Treat proteinuria with RAAS (first) ACR: no immunosuppressive treatment 
EULAR/ERA-EDTA: proteinuria >1 g/24 h, especially 
in the presence of glomerular haematuria; low to 
moderate doses oral glucocorticoids (0.25-0.5 
mg/kg/d) alone or in combination with AZA (1-2 
mg/kg/d), if necessary 
KDIGO: proteinuria <1 g/24 h: treat as dictated by 
extrarenal manifestations. Proteinuria >3 g/24 h: 
corticosteroids or CNI as described for MCD 
GEAS: significant proteinuria (>1-2 g/24 h) and/or 
deteriorated renal function that is not attributable to 
functional factors; steroids up to 0.5 mg/kg/d, 
possibly plus AZA or MMF for 6-12 months 
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 Common view Differences 
Induction 
treatment 
class III/IV 
without 
crescents 
(and/or other 
adverse 
parameters) 
Oral glucocorticoids with or without 3 iv pulses 
methylprednisolone (MP) at start induction 
+ ivCYC or MMF 
Dosage and preferences for different severities (see 
also next section) and ethnic groups: 
Glucocorticoids:  
 MP dose ranging from 250 to 1000 mg/d (or 
weight dependent in children) 
 MP not always recommended; dependent on 
combination with MMF or ivCYC, or on severity 
 Oral dose ranging from 0.5 to 1 mg/kg/d, 
sometimes depending on combination with MP, 
MMF or ivCYC 
 Tapering schedule: unclear 
MMF:  
 Ranging from 2 to 3 g total daily dose 
 Sometimes preferred over ivCYC in patients of 
African or Hispanic descent  
ivCYC: 
 Either high dose (NIH; 0.5-1 g/m
2
 monthly for 6 
months) or low dose (Eurolupus; 500 mg 
fortnightly for 3 months): low dose usually 
preserved for (European) Caucasians and 
sometimes only for relatively mild disease 
 In case of low dose ivCYC, combine pulses MP 
Induction 
treatment 
class IV or 
IV/V with 
crescents 
(and/or other 
adverse 
parameters) 
No consensus KDIGO, DWP, CARRA: same as without crescents 
(and/or other adverse parameters) 
ACR: ivCYC or MMF + 3 iv pulses MP + oral 
glucocorticoids; MMF and oral glucocorticoids at 
highest doses (MMF 3 g total daily dose; oral 
glucocorticoids 1 mg/kg/d) 
EULAR/ERA-EDTA: high dose (see above) ivCYC can 
also be prescribed 
GEAS: 3 pulses MP (250-1000mg/d) and include 
ivCYC in regimen 
Induction 
treatment 
class V 
If nephrotic range proteinuria (≥3 g/24 h): oral 
glucocorticoids (0.5 mg/kg/d) combined with 
other immunosuppressive medication (except in 
GEAS) 
GEAS: also in patients with non-nephrotic range 
proteinuria; oral glucocorticoids up to 1 mg/kg/d 
(max 60 mg) combined with either ivCYC, MMF, AZA 
or CNIs 
Type of additional immunosuppressive medication: 
 EULAR/ERA-EDTA: preferably MMF (3 g total 
daily dose), alternatives; high dose ivCYC, CNIs 
or rituximab 
 ACR: MMF (2-3 g total daily dose) 
 KDIGO: ivCYC, CNIs, MMF or AZA 
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 Common view Differences 
Treatment 
class VI 
Suggestions from different guidelines: 
 Prepare for renal replacement therapy 
 Treat with immunosuppressives only as 
dictated by extrarenal disease 
 Maintain RAAS inhibition and monitor for 
complications 
- 
Maintenance 
treatment 
Class III/IV: 
 AZA (1.5-2.5 mg/kg/d) or MMF (1-2 g/d) 
 Plus low dose oral glucocorticoids 
Class V:  
 As class III/IV 
 CNIs can be considered 
Class III/IV: 
 EULAR/ERA-EDTA recommends MMF over AZA 
if there was a response to MMF during the 
induction phase 
 GEAS recommends MMF over AZA 
 Duration of treatment: at least 3 years 
(EULAR/ERA-EDTA) or at least 1 (KDIGO) or 2 
(GEAS) years after (complete) remission 
Adjunctive 
treatment 
HCQ for all unless contraindicated; screening 
ophthalmologist for retinopathy at baseline and 
yearly after 5 years (recommended by most) 
RAAS inhibition for proteinuria and to control 
blood pressure (<130/80 mmHg) 
Treat hyperlipidaemia with statins, target LDL 
<100 mg/dl or 2.6 mmol/l 
Other treatment suggestions supported by one 
or more guidelines: 
 Calcium and vitamin D supplements 
 Bisphosphonates depending on 
glucocorticoid dose, age and renal function 
 Low dose acetylsalicylic acid in patients with 
aPL 
 Consider anti-coagulant treatment in 
patients with nephrotic syndrome and 
albumin <20 g/l 
 Avoid vaccination with live or attenuated 
viruses during immune suppression 
 GnRH analogues in women over 35 y if 
cumulative CYC dose >10 g 
Required level of proteinuria to start treatment with 
RAAS inhibition: ranging from 0.5 g/24h or uPCR >50 
mg/mmol to 1.0 g/24 h, if specified at all 
 
 
Treatment for 
refractory 
disease 
Switch from ivCYC to MMF or vice versa with or 
without 3 accompanying iv pulses MP 
Alternative treatments: rituximab (as add-on or 
monotherapy), CNIs or intravenous 
immunoglobulins 
- 
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 Common view Differences 
Pregnancy Continue HCQ 
Allowed: glucocorticoids (non-fluorinated), AZA, 
CNIs, methyldopa, labetalol or nifedipine 
Not-allowed: MMF, ivCYC, RAAS inhibitor 
Consider low dose acetylsalicylic acid to reduce 
risk of pre-eclampsia and fetal loss 
Monitor closely, preferably by a multi-
disciplinary team 
Do not taper glucocorticoids or AZA during 
pregnancy or within 3 months thereafter 
(KDIGO) 
Plan pregnancy when: 
 EULAR/ERA-EDTA: stable (uPCR <50 mg/mmol, 
GFR preferably over 50 ml/min) for 6 months 
 GEAS: (partial) remission for 6 months  
 KDIGO: preferably delay until complete 
remission 
 ACR: not specified 
 
Vascular 
complications 
No consensus EULAR/ERA-EDTA: ASPN; consider HCQ and/or 
antiplatelet/anticoagulant treatment. In case of 
definite APS, start anticoagulant treatment 
ACR: treat TMA with plasma exchange therapy 
KDIGO/GEAS: ASPN; anticoagulant treatment (INR 2-
3) 
KDIGO: treatment for TTP is plasma exchange as in 
patients without lupus 
Monitoring Determine at each visit: body weight, BP, sCr, 
proteinuria, urinary sediment, C3/C4, anti-dsDNA 
(and serum albumin and complete blood count) 
Schedule visits: 
 Active nephritis: approximately monthly, or 
more frequently 
 No active nephritis: every 3-6 months 
ACR:  
 Some parameters can be determined at larger 
intervals than others; BP and urinalysis most 
often, anti-dsDNA least often 
 Separate schedule for pregnancy; in short, if 
active LN, once a month, and if LN in history but 
none currently, BP and urinalysis once a month 
and uPCR, sCr, C3/C4 and anti-dsDNA every 3 
months 
Management 
of ESRD 
Renal replacement therapy: 
 Increased risk of infection in patients still on 
immunosuppressives (EULAR/ERA-EDTA) 
 Increased risk of vascular access thrombosis 
in patients with aPL (EULAR/ERA-EDTA) 
 If lupus is inactive offer peritoneal dialysis; if 
lupus is active offer haemodialysis (GEAS) 
Transplantation: 
 Determine aPL; associated with increased 
risk of vascular events in the transplant 
Transplantation: 
 If lupus activity absent or low for 3-6 
(EULAR/ERA-EDTA) or 6-12 (GEAS) months 
 
Table 2. Guidelines compared; common views and differences 
uPCR 100 mg/mmol ≡ 1000 mg/g ≡ 1(g/g) ≈ 1 g/24 h [55] 
Abbreviations: ACR=American College of Rheumatology; aPL=antiphospholipid antibodies; APS=antiphospholipid syndrome; 
APSN=antiphospholipid-associated nephropathy; AZA=azathioprine; BP=blood pressure; CARRA=Childhood Arthritis and 
Rheumatology Research Alliance; CNI=calcineurin inhibitor; anti-dsDNA=antibodies to double stranded DNA; DWP=Dutch 
Working Party on Systemic Lupus Erythematosus; ESRD=end-stage renal disease; EULAR/ERA-EDTA=European League 
Against Rheumatism and European Renal Association–European Dialysis and Transplant Association; GEAS= Systemic auto-
immune disease group of the Spanish Society of Internal Medicine and Spanish Society of Nephology; GFR=glomerular 
filtration rate; HCQ= hydroxychloroquine; HPF=high power field; ISN/RPS=International Society of Nephrology/Renal 
Pathology Society; ivCYC=intravenous cyclophosphamide; KDIGO= Kidney Disease: Improving Global Outcomes 
Glomerulonephritis Work Group; LN=lupus nephritis; MCD=minimal change disease; MMF=mycophenolate mofetil; 
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MP=methylprednisolone; NIH=National Institute of Health; RAAS=renin-angiotensin-aldosterone system; RBC=red blood 
cell; sCr=serum creatinine; uPCR=urine protein-creatinine ratio. 
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 Common view Differences 
Complete 
response 
Proteinuria: uPCR <50 mg/mmol or <500 
mg/g, or <0.5 g/24 h (except CARRA) 
Plus (near) normal renal function 
 
Proteinuria: uPCR <200 mg/g or age appropriate 
(CARRA) 
Renal function: ranging from normalization to baseline 
to baseline plus 25%. Or sCr <1.2 mg/dl (106 µmol/l) 
(GEAS) 
Plus inactive urinary sediment (<5 red blood cells/HPF, 
<5 leukocytes/HPF, no casts) (GEAS/CARRA) 
Plus serum albumin >30 g/dl (GEAS) 
Partial 
response 
≥50% decrease in proteinuria, to at least 
sub-nephrotic levels (except CARRA) 
Plus stabilization or improvement of sCr 
GEAS: if proteinuria >3.5 g/24 h, partial response if 
proteinuria <3.5 g/24 h 
Renal function: 
 EULAR/ERA-EDTA: (near) normal 
 KDIGO/GEAS: stabilization  (±25%) or improvement 
of sCr 
 DWP: sCr within 125% of baseline 
CARRA: different approach, for details see table S2 
Flare Increase or recurrence of active urinary 
sediment (haematuria from <5 RBC/HPF to 
>15 RBC/HPF 
Or an increase in sCr (exact criteria different 
in the different guidelines, for details see 
table S2) 
Or an increase in proteinuria: 
 If proteinuria <500 mg/g (complete 
response) an increase to ≥1000 mg/g is 
required 
 If proteinuria >500 mg/g (partial 
response) a doubling of uPCR to ≥2000 
mg/g is required (EULAR/ERA-EDTA, 
KDIGO, GEAS) 
Depending on which of the above mentioned 
criteria are met, the flare can be designated 
at either nephrotic or nephritic. 
With respect to proteinuria the bar is raised in the DWP 
guideline and lowered in the CARRA guideline: 
 DWP: development of nephrotic syndrome if 
lowest proteinuria was <2 g/24 h, or proteinuria of 
≥1.5 g/24 h in previously non-proteinuric patient 
 CARRA: after a complete response an increase to 
>500 mg/g is required and after a partial response 
a doubling of sCr to >1000 mg/g 
Refractory 
disease 
There is no consensus between guidelines 
and some guidelines state that a consensus 
was not reached 
For details see table S2 
Table 3. Definitions of response to treatment and flares; common views and differences 
 uPCR 100 mg/mmol ≡ 1000 mg/g ≡ 1(g/g) ≈ 1 g/24 h [55] 
Abbreviations: ACR=American College of Rheumatology; CARRA=Childhood Arthritis and Rheumatology Research Alliance; 
DWP=Dutch Working Party on Systemic Lupus Erythematosus; EULAR/ERA-EDTA=European League Against Rheumatism 
and European Renal Association–European Dialysis and Transplant Association; GEAS= Systemic auto-immune disease 
group of the Spanish Society of Internal Medicine and Spanish Society of Nephrology; HPF=high power field; KDIGO= Kidney 
Disease: Improving Global Outcomes Glomerulonephritis Work Group; RBC=red blood cell; sCr=serum creatinine; 
uPCR=urine protein-creatinine ratio. 
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 EULAR/ERA-EDTA ACR KDIGO GEAS DWP CARRA 
From European League Against 
Rheumatism and European 
Renal Association–
European Dialysis and 
Transplant Association  
American College of 
Rheumatology 
Kidney Disease: Improving 
Global Outcomes 
Glomerulonephritis Work 
Group 
Systemic auto-immune disease 
group of the Spanish Society of 
Internal Medicine and Spanish 
Society of Nephology 
Dutch Working Party on 
Systemic Lupus Erythematosus 
Childhood Arthritis 
and Rheumatology 
Research Alliance 
Indication for 
renal biopsy 
 Reproducible 
proteinuria ≥0.5 g/24 
h, especially with 
glomerular haematuria 
and/or cellular casts 
(2C) 
 Consider: 
 Persisting isolated 
glomerular haematuria 
 Isolated leucocyturia 
(other causes 
excluded) 
 Unexplained renal 
insufficiency with 
normal urinary 
findings 
 
 Increasing serum 
creatinine without 
compelling alternative 
causes (such as sepsis, 
hypovolemia, or 
medication) (C) 
 Confirmed proteinuria of 
≥1g/24 h (C) 
 Combinations of the 
following (confirmed in 2 
tests in short period of 
time and in absence of 
alternative causes) (C) 
 Proteinuria ≥0.5 g/24 h 
AND haematuria (≥5 
RBCs/HPF) 
 Proteinuria ≥0.5 g/24 h 
AND cellular casts 
Not provided  Confirmed proteinuria: ≥0.5 
g/24 h urine samples or 
protein/creatinine ratio in 
first morning samples ≥0.5, 
or a ratio ≥0.5 ratio 
calculated in 24-hour urine 
sample, or active urinary 
sediment (microhaematuria/ 
leucocyturia/casts) 
 Inexplicable decrease in 
renal function (NG) 
 
 >0.5 g/24 h proteinuria, 
independent of presence 
of haematuria or elevated 
serum creatinine (C) 
 ≤0.5 g/24 h proteinuria: 
 Normal creatinine and 
microscopic haematuria → 
consider biopsy 
 Elevated creatinine 
without microscopic 
haematuria → consider 
biopsy when either: 
o Persistent elevation of 
serum creatinine of >30% 
o Other causes of renal 
impairment are excluded 
o Positive antiphospholipid 
antibodies 
o Extrarenal 
involvement/presence of 
anti-dsDNA 
antibodies/hypo-
complementaemia (C) 
Not provided 
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 EULAR/ERA-EDTA ACR KDIGO GEAS DWP CARRA 
Biopsy 
evaluation 
 At least 8 glomeruli 
 Score according to 
ISN/RPS (2C) with 
assessment of active 
and chronic 
glomerular (1A) and 
tubulo-interstitial 
changes (2B) and of 
vascular lesions 
associated with 
aPL/APS (3C) 
 Examine with HE, PAS, 
Ag, trichrome, IF and if 
possible EM 
Not provided Not provided  Classify according to 
ISN/RPS (NG) 
 Optimal optical microscope 
and IF techniques and EM 
recommended (NG) 
 Quantified data on activity 
and chronicity and a 
description of vascular and 
interstitial lesions should be 
provided (NG) 
Not provided According to ISN/RPS 
classification system 
Indication for 
repeat biopsy 
In selected cases: 
 Worsening or 
refractory to 
treatment (failure to 
decrease proteinuria 
≥50%, persistent 
proteinuria beyond 1 
year and/or worsening 
of GFR)  
 At relapse, to 
demonstrate change 
or progression in 
histological class, 
change in activity and 
chronicity index, to 
provide prognostic 
information and to 
detect other 
pathologies (3C) 
Not provided Consider if: 
 No complete remission 
after 1 year (NG) 
 During relapse if there is 
suspicion that the 
histologic class has 
changed or there is 
uncertainty whether a 
rise in sCr or proteinuria 
represents disease 
activity or chronicity 
(NG) 
 In patients with 
worsening sCr and/or 
proteinuria after 
completing one of the 
initial treatment 
regimens in order to 
distinguish active LN 
from scarring (NG) 
Only if findings can lead to a 
change in treatment or prognosis 
(NG): 
 Increase or reappearance of 
proteinuria, nephrotic 
syndrome, or active urinary 
sediment, especially if the 
first biopsy revealed a non-
proliferative form 
 Increased sCr or inexplicable 
evolution towards renal 
failure 
 Refractory to 
immunosuppressives 
 Uncertainty with regard to 
activity/chronicity of renal 
lesions (deciding upon 
treatment) 
 Suspicion of non-lupus 
related nephropathy 
Only if therapeutic 
consequences (C): 
 Persistence proteinuria 
after partial response 
(despite optimal 
supportive treatment): 
active or chronic disease 
or progression to FSGS 
 Failure to respond at 12 
months, in order to 
differentiate between 
chronic and active 
No consensus 
reached 
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Treatment 
class II 
Proteinuria >1 g/24 h 
despite RAAS inhibition, 
especially in the presence 
of glomerular haematuria; 
low to moderate doses oral 
glucocorticoids (0.25-0.5 
mg/kg/d) alone or in 
combination with AZA (1-2 
mg/kg/d) 
No immunosuppressive 
treatment (C) 
 Proteinuria <1 g/24 h: 
treat as dictated by 
extrarenal 
manifestations (2D) 
 Proteinuria >3 g/24 h: 
corticosteroids or CNI as 
described for MCD (2D) 
Significant proteinuria (>1-2 g/24 
h despite renal protective 
treatment) and/or deteriorated 
renal function that is not 
attributable to functional factors; 
steroids up to 0.5 mg/kg/d, 
possibly plus AZA or MMF for 6-
12 months (2D) 
Not provided Not provided 
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Induction 
treatment class 
III/IV without 
crescents 
(and/or other 
adverse 
parameters) 
 For A or A/C classes 
(ISN/RPS 2003) 
 Regimens: 
 Glucocorticoids: 3 iv 
pulses MP; 500-750 
mg/d (3C) + oral; 0.5 
mg/kg/d for 4 weeks, 
reducing to ≤10 mg/d 
by 4-6 months (C)  
 MMF (3 g total daily 
dose) for 6 months 
(seems preferable) 
(1A) or low dose ivCYC 
(1B) (in Caucasians) 
 African descent: MMF 
might be better but 
more further 
confirmation needed 
 Mild cases: AZA (2 
mg/kg/d) can be 
considered (2B) 
 Regimens: 
 Glucocorticoids: 3 iv 
pulses MP; 500-1000 
mg/d + oral; 0.5-1 
mg/kg/d and taper (C) 
 MMF (2-3 g total daily 
dose; Asian 2 g 
considered) or ivCYC 
(white European high or 
low dose (B); rest high 
dose) 
 African Americans and 
Hispanics: favour MMF 
 MMF over ivCYC if child 
bearing concerns 
 Keep up for 6 months 
unless worsening at 3 
months 
 Regimens: 
 Glucocorticoids: 3 iv 
pulses MP (widely used 
for more severe disease, 
no dose provided) + oral; 
(1A) up to 1 mg/kg/d 
and taper according to 
clinical response over 6-
12 months 
 MMF (1B) or ivCYC (1B); 
low dose ivCYC effective 
in Caucasians with not 
too severe disease, 
unclear if also case for 
other ethnicities and 
severe disease 
 MMF equivalent to high 
dose ivCYC in short 
term, not clear for long-
term 
 If worsening LN (rising 
sCr, worsening 
proteinuria) in first 3 
months  change to 
alternative initial 
(induction) therapy or 
repeat kidney biopsy 
(2D) 
 Race: further 
information required 
 Regimens: 
 Glucocorticoids: 3 iv pulses 
MP (250-1000 mg/d) in 
presence of extracapillary 
proliferation or acute 
deterioration of renal 
function (2C) + oral; start up 
to 1 mg/kg/d (max 60 mg), 
0.5 mg/kg/d can be used 
with concomitant pulses of 
MP (2C) and if possible taper 
to 5 mg/d 
 MMF 2-2.5 g/d (1B) or 
ivCYC; either monthly 750 
mg/m
2
 for 6 months (NIH), 
or fortnightly 500 mg for 3 
months (Eurolupus) with 3 
MP pulses (750 mg/d), 
followed by oral prednisone 
0.5 mg/kg/d (1B) 
 
 Regimens: 
 MMF to 3 g total daily 
dose in 3 weeks + oral 
glucocorticoids; 1 
mg/kg/d, max 60 mg (A) 
and taper: after 4 weeks 
10 mg every 4 weeks to 20 
mg, followed by 5 mg 
every 4 weeks to 10 mg 
 Low dose ivCYC + 3 iv 
pulses MP + oral 
glucocorticoids 0.5-1 
mg/kg/d (A) and taper: 
after 4 weeks every 2 
weeks with 2.5 mg to 5-7.5 
mg at 30 months 
 Race: MMF may be better 
in Blacks 
 Regimens: 
 Glucocorticoids: 
3 iv pulses MP 
(30 mg/kg/dose 
up to 1000 
mg/dose) and/or 
oral 
glucocorticoids 
depending on 
which of the 3 
scheme’s 
(primarily oral, 
primarily iv or 
mixed oral/iv) is 
chosen 
 ivCYC; 6 monthly 
doses, initial 
dose 500 mg/m
2
, 
subsequent 
doses higher but 
not more than 
1500 mg (C) 
(most often used 
in practice), or  
MMF; 600 
mg/m
2
/d twice 
daily with a max 
of 1500 mg twice 
a day (C) 
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Induction 
treatment class 
IV or IV/V with 
crescents 
(and/or other 
adverse 
parameters) 
With adverse prognostic 
profile (acute deterioration 
renal function, substantial 
cellular crescents and/or 
fibrinoid necrosis): 
 Same regimen (MMF 
(2B); low dose ivCYC 
(4C)) 
 CYC can also be 
prescribed monthly iv 
at higher doses (0.75-1 
g/m
2
) for 6 months 
(1A) or orally (2-2.5 
mg/kg/d) for 3 months 
(3B) 
Either CYC or MMF(3 g total 
daily dose, instead of 2-3 g) 
(C) + 3 pulses MP and oral 
glucocorticoids at 1 mg/kg/d, 
instead of 0.5-1 mg/kg/d 
 
Not different from without 
crescents (and/or other 
adverse parameters) 
 3 pulses MP (250-1000 
mg/d) in presence of 
extracapillary proliferation 
or acute deterioration of 
renal function (2C) 
 Include ivCYC if severe 
decrease in renal function 
(sCr >3 mg/dl) or cellular 
crescents or fibrinoid 
necrosis (2C) 
Not different from without 
crescents (and/or other 
adverse parameters) 
Not different from 
without crescents 
(and/or other adverse 
parameters) 
Induction 
treatment class 
V 
 If nephrotic range 
proteinuria (≥3 g/24 
h): prednisone (0.5 
mg/kg/d) and MMF 3 g 
total daily dose for 6 
months(2B) 
 Alternatives: high dose 
ivCYC (2A), CNIs 
(ciclosporin (2A); 
tacrolimus (3B)) or 
rituximab (4C) 
 
If nephrotic range proteinuria 
(≥3 g/24 h): prednisone (0.5 
mg/kg/d) and MMF 2-3 g 
total daily dose (A) 
 
 If normal kidney 
function, non-nephrotic 
range proteinuria  no 
immunosuppressives 
unless dictated by 
extrarenal disease (2D) 
 Persistent nephrotic 
range proteinuria: 
corticosteroids plus 
immunosuppressive 
(ivCYC (2C), CNI (2C), 
MMF (2D) or AZA (2D)) 
 Oral steroids up to 1 
mg/kg/d (max 60 mg) 
initially and taper 
 Plus one of: 
 ivCYC (1B), dose as in class 
III/IV 
 CNIs (ciclosporin, dose 2-5 
mg/kg/d (1B); tacrolimus, 
dose 0.15-0.2 mg/kg/d (2C)) 
 MMF (1B), dose as III/IV 
 AZA (1C), dose 1.5-2 
mg/kg/d 
Not provided Not provided 
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Treatment 
class VI 
Not provided Prepare for renal 
replacement therapy 
Treat with corticosteroids 
and immunosuppressives 
only as dictated by extrarenal 
disease (2D) 
 Maintain RAAS inhibition 
and monitor for 
complications (2C) 
 Slowly decrease immune 
suppression until it can be 
discontinued (unless 
dictated by extrarenal 
disease) (1B) 
Not provided Not provided 
Maintenance 
treatment 
 Class III/IV: 
 AZA (2 mg/kg/d) or 
MMF (2 g/kg/d) (1A) 
for at least 3 years (3C) 
 If response to MMF at 
induction, stay on 
MMF (C) 
 Plus low dose oral 
glucocorticoids (5-7.5 
mg/d) 
 Pure class V:  
 As class III/IV 
 CNIs can be 
considered (4C) 
 Class III/IV: 
 AZA or MMF (A) 
 Plus low dose oral 
glucocorticoids 
 Class III/IV: 
 AZA (1.5-2.5 mg/kg/d) or 
MMF (1-2g/d) (1B) 
 Plus low dose oral 
glucocorticoids (≤10 
mg/d prednisone 
equivalent) 
 CNIs if intolerant to 
MMF or AZA (2D) 
 After complete 
remission, continue 
maintenance for at least 
1 year (2D) 
 No complete remission 
after 1 year  consider 
repeat biopsy (NG) 
 If during tapering renal 
function deteriorates 
and/or proteinuria 
worsens, increase to 
previous level (2D) 
 Class III/IV: 
 MMF (1.5-2 g/d) (over AZA 
(1.5-2 mg/kg/d)) (2A) 
 Plus low dose oral 
glucocorticoids 
 Duration of treatment: at 
least 2 years after remission 
has been reached (2C) 
 Pure Class V:  
 Low dose steroids and MMF, 
CNIs or AZA (2B) 
 Dosage and duration as in 
class III and IV 
 Class III/IV:  
 MMF over AZA (A) 
 Plus low dose oral 
glucocorticoids 
Not provided 
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Adjunctive 
treatment 
 HCQ for all (3C); 
screening 
ophthalmologist for 
retinopathy (baseline 
and yearly after 5 
years) 
 RAAS inhibition for 
patients with 
proteinuria (uPCR >50 
mg/mmol) or 
hypertension (target 
<130/80) (2B) 
 Statins (target LDL 
<100 mg/dl = 2.58 
mmol/l)) (C) 
 Acetylsalicylic acid in 
patient with aPL (C), 
calcium and vitamin D 
supplementation (C), 
and immunisation with 
non-live vaccines (C) 
may reduce treatment 
or disease related 
comorbidities and 
should be considered 
 Consider anti-
coagulant treatment in 
nephrotic syndrome 
with albumin <20 g/l, 
especially if also aPL 
(C) 
 Background HCQ unless 
contraindicated (C) 
 Proteinuria ≥0.5 g/24 h 
→ RAAS inhibition (A) 
 Control hypertension, 
target ≤130/80 (A) 
 LDL >100 mg/dl → 
statins (C) 
 
 HCQ for all unless 
contraindicated (2C); 
screening 
ophthalmologist for 
retinopathy (baseline 
and yearly after 5 years) 
 Leuprolide/testosterone 
should be offered to 
protect fertility 
 In general in glomerular 
disease: 
 Blood pressure control 
 Treatment of 
hyperlipidaemia 
 RAAS inhibition in 
managing proteinuria 
 Manage 
hypercoagulability 
 HCQ for all unless 
contraindicated (1B); 
screening ophthalmologist 
for retinopathy (baseline 
and yearly thereafter) (1C) 
 RAAS inhibition in patients 
with hypertension and/or 
proteinuria (1B) 
 Weight loss against 
proteinuria (1C) if obese 
 Reduce cardiovascular risks 
(1B) (lifestyle, BP <130/80, 
statins) 
 Calcium and vitamin D (1A) 
for patients on oral 
glucocorticoids; 
bisphosphonates if older 
than 50 years (1A) 
 Drugs for gastric protection 
if history of gastrointestinal 
haemorrhage or peptic ulcer 
disease, or with combination 
of corticosteroids and 
NSAIDs (1B) 
 Avoid vaccines containing 
live or attenuated viruses 
during immune suppression 
(1B) 
 GnRH analogues in women 
over 35 y if cumulative CYC 
dose >10 g (1C) 
 Background HCQ (B); 
screening by 
ophthalmologist for 
retinopathy (baseline and 
yearly after 5 years) 
 Proteinuria ≥1 g/24 h → 
RAAS inhibition (A) 
 Hypertension control, 
target <130/80 (A; if 
proteinuria >1 g/24h) 
 Treatment 
hyperlipidaemia (C); target 
2.6 mmol/l 
 Calcium and vitamin D 
(osteoporosis) for patients 
on oral glucocorticoids; 
bisphosphonates if >15 mg 
oral glucocorticoids daily 
or if >70 years old and 7.5-
15 mg oral glucocorticoids 
daily unless clearance 
<60ml/min or pregnancy 
wish 
 Low dose acetylsalicylic 
acid if aPL positive 
 Coumarines considered if 
nephrotic syndrome with 
albumin <20g/l (C) 
 Lifestyle 
 
Not provided 
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Treatment for 
refractory 
disease 
 Switch from ivCYC to 
MMF or vice versa 
(4C), or rituximab (4C)  
 Other options: CNIs, 
ivIg, plasma exchange 
for rapid progressive 
glomerulonephritis, or 
immunoadsorption 
 Switch from ivCYC to 
MMF or vice versa 
accompanied by 3 pulses 
MP (C) 
 In some cases rituximab 
can be used  
 No consensus on CNI 
 In patients with 
worsening sCr and/or 
proteinuria after 
completing one of the 
initial treatment 
regimens, consider 
performing a repeat 
biopsy to distinguish 
active LN from scarring 
(NG)  if active LN, 
treat with alternative 
induction therapy (NG) 
 Responders who have 
failed more than one 
induction may be 
treated with rituximab, 
ivIg or CNIs (2D) 
 Switch from CYC to MMF or 
vice versa (1A) 
 Alternative treatments (if 
above fails): rituximab (2B), 
CNIs (2B), ivIg (2C) or 
combining drugs (2B) 
 Change treatment scheme if 
there are no sign of 
response before completing 
the sixth month of induction 
(1B) 
 Rule out presence of other 
diseases and ensure 
compliance (NG) 
 If nothing works, consider a 
new biopsy 
 Switch from ivCYC to MMF 
or vice versa accompanied 
by 3 pulses MP (C) 
 Consider: rituximab, 
tacrolimus, NIH ivCYC 
Not provided 
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Pregnancy  If stable (uPCR <50 
mg/mmol, GFR 
preferably over 50 
ml/min) for 6 months 
(2B)  
 Acceptable 
medications: HCQ 
(3B), low dose 
prednisone (4C), 
azathioprine (4C) or 
CNIs (4C)  
 Intensity of treatment 
should not be reduced 
in anticipation of 
pregnancy (C) 
 Consider acetylsalicylic 
acid to reduce risk of 
pre-eclampsia (3C) 
 Assess at least every 4 
weeks (C) 
 Prior LN but no current 
systemic or renal 
activity: no nephritis 
medication 
 Mild systemic activity: 
HCQ (200-400 mg daily) 
 Clinically active nephritis 
or substantial extrarenal 
disease: oral 
glucocorticoids, if 
necessary AZA (max 2 
mg/kg) (C) 
 Preferably delay 
pregnancy until in 
complete remission (2D) 
 Don’t use CYC, MMF, 
ACE-I and ARBs during 
pregnancy (1A) 
 Continue HCQ (2B) 
 If pregnant while on 
MMF, switch to AZA (1B) 
 Relapse: corticosteroids 
possibly with AZA (1B) 
 Don’t taper 
corticosteroids or AZA 
during pregnancy or 
within the 3 months 
after (2D) 
 Low dose aspirin to 
decrease risk of fetal 
loss (2C) 
 Plan after at least 6 months 
of (partial) remission (1B) 
 Monitor closely by multi-
disciplinary team (NG) 
 For blood pressure control 
suspend RAAS inhibitors and 
use methyldopa, labetalol or 
nifedipine (1B) 
 Avoid teratogenic drugs 
(CYC, MMF, MTX); AZA safe 
 Continue HCQ during 
pregnancy 
 Aspirin at low doses (100 
mg/d) before week 12 to 
reduce risk of pre-eclampsia 
and fetal loss (1A) 
Not provided Not provided 
Vascular 
complications 
 In patients with APSN; 
consider HCQ (C) 
and/or antiplatelet/ 
anticoagulant 
treatment (C)  
 Definite APS → 
anticoagulant 
treatment 
Treat TMA with plasma 
exchange therapy 
 APS involving the kidney 
(APSN)  with or without 
LN  anticoagulation 
INR 2-3 (2D) 
 If TTP  plasma 
exchange as in patients 
without lupus (2D) 
 Maintain indefinite 
anticoagulant treatment in 
patients with ASPN (2C) 
 Treat thrombosis of major 
renal vessels with prolonged 
anticoagulation (1B), as in 
non-APS associated 
thrombosis 
Not provided  Not provided 
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Monitoring  Active LN should be 
regularly monitored by 
determining at each 
visit body weight, BP, 
sCr and eGFR, serum 
albumin, proteinuria, 
urinary sediment 
(microscopic 
evaluation), serum C3 
and C4, serum anti-
dsDNA and complete 
blood cell count  
 Anti-phospholipid 
antibodies and lipid 
profile should be 
measured at baseline 
and monitored 
intermittently  
 Visits should be 
scheduled every 2-4 
weeks for the first 2-4 
months after diagnosis 
or flare (C) and every 
3-6 months for life (C) 
 Active nephritis at onset 
of treatment: BP 1, urine 
1, uPCR 1, sCr 1, C3/C4 
2, anti-DNA 3 (monthly 
intervals) 
 Previous active 
nephritis, none 
currently: BP 3, urine 3, 
uPCR 3, sCr 3, C3/C4 3, 
anti-DNA 6 (monthly 
intervals) 
 Pregnant with active GN 
at onset of treatment: 
BP 1, urine 1, uPCR 1, 
sCr 1, C3/C4 1, anti-DNA 
1 (monthly intervals) 
 Pregnant with previous 
nephritis, none 
currently: BP 1, urine 1, 
uPCR 3, sCr 3, C3/C4 3, 
anti-DNA 3 (monthly 
intervals) 
 No prior or current 
nephritis: BP 3, urine 6, 
uPCR 6, sCr 6, C3/C4 6, 
anti-DNA 6 (monthly 
intervals) (C) 
Not provided.  Every 3 months by 
determining creatinine 
proteinuria, anti-dsDNA, C3 
and C4 (NG) 
 Proteinuria should be 
measured in 24-hour urine, 
follow-up may only include 
protein/creatinine ratio in 
first morning urine (NG) 
 At baseline more lab tests 
particularly those relevant 
for assessing cardiovascular 
risks (see detailed scheme in 
table 8 (in original article)) 
Not provided Not provided 
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Management 
of ESRD 
 Renal replacement 
therapy: possible 
increased risk of 
infection in patients 
still on 
immunosuppressives 
(2B) and of vascular 
access thrombosis in 
patients with aPL (3C) 
 Transplantation:  
 If lupus activity absent 
or low for at least 3-6 
months (3C) 
 Determine aPL; 
associated with 
increased risk of 
vascular events in the 
transplant (2B) 
Not provided Not provided  ESRD: 
 If reached during flare, 
induction treatment should 
be continued for 4-6 months 
after beginning dialysis, until 
lack of recovery is observed 
(NG) 
 Decrease 
immunosuppressives to 
levels required for 
extrarenal lupus (1B) 
 Renal replacement therapy: 
 Inactive lupus  offer PD; 
active lupus  offer HD (2C) 
 Increase prophylaxis against 
infections for PD and HD 
 Transplantation: 
 If lupus activity absent or 
low for 6-12 months (NG) 
 Determine aPL; associated 
with increased risk of 
vascular events in the 
transplant (NG) 
Not provided Not provided 
Table S1. Guidelines compared; overview of all guidelines 
ivCYC high dose (NIH regimen) = 0.5-1 g/m2 monthly for 6 months; ivCYC low dose (Eurolupus regimen) = 500 mg every 2 weeks for 3 months 
Abbreviations: A=active; (A)/(B)/(2A)=level of evidence (for criteria see table S3); Ag=silver staining; aPL=anti-phospholipid antibodies; APS=antiphospholipid syndrome; APSN=anti-phospholipid syndrome-
associated nephropathy; AZA=azathioprine; BP=blood pressure; C=chronic; CNI=calcineurin inhibitor; (e)GFR=(estimated) glomerular filtration rate; EM=electron microscopy; FSGS=focal segmental 
glomerulosclerosis; GnRH=gonadotrophin-releasing hormone; HCQ=hydroxychloroquine; HD=haemodialysis; HE=haematoxylin and eosin staining; IF=immunofluorescence; ISN/RPS=International Society of 
Nephrology/Renal Pathology Society; ivCYC=intravenous cyclophosphamide; ivIg=intravenous immunoglobulins; LN=lupus nephritis; MCD=minimal change disease; MMF=mycophenolate mofetil; 
MP=methylprednisolone; NG=not graded (level of evidence); NSAID=non-steroidal anti-inflammatory drug; PAS=periodic acid Schiff staining; PD=peritoneal dialysis; RBC=red blood cell; sCr=serum creatinine; 
TMA: thrombotic microangiopathy; TTP=thrombocytopenic purpura; uPCR=urine protein-creatinine ratio. 
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Complete 
response 
 uPCR <50 mg/mmol  
[approx. <0.5 g/24 h]  
 Plus (near) normal 
(within 10% of normal 
GFR) renal function 
 A decline in the uPCR to 
<500mg/g  
 Plus return of sCr to 
previous baseline  
 
 Proteinuria ≤0.5 g/24h 
 Plus sCr <1.2 mg/dl (or decrease 
to initial values or ±15% of 
baseline value in patients with 
sCr ≥1.2 mg/dl [106 µmol/l])  
 Plus inactive urinary sediment 
(≤5 RBCs/HPF (debatable), ≤5 
WBCs/HPF, 0 RBC casts)  
 Plus serum albumin >3g/dl 
 Proteinuria <0.5 g/24 h 
 And/or sCr within 125% of the 
baseline value at 6 to 12 months 
after the start of induction 
therapy 
 uPCR <200 mg/g or age 
appropriate 
 Plus normalization of renal 
function  
 Plus inactive urine sediment (<5 
WBCs/HPF, <5 RBCs/HPF, and no 
casts) 
Partial 
response 
 ≥50% reduction in 
proteinuria to 
subnephrotic levels 
 Plus (near) normal 
renal function 
 It should be achieved 
preferably by 6 
months but no later 
than 12 months 
following treatment 
initiation 
 ≥50% decrease in uPCR 
 If there was nephrotic-
range proteinuria (uPCR 
≥3000mg/g), improvement 
requires a ≥50% reduction 
in uPCR, and a uPCR <3000 
mg/g 
 Plus stabilization (±25%), 
or improvement of sCr, 
but not to normal 
 In patients with baseline 
proteinuria <3.5g/24h, >50% 
reduction in proteinuria 
compared to initial values  
 In patients with ≥3.5 g/24h, 
decreased proteinuria <3.5 
g/24h  
 Plus stabilisation (±25%) or 
improvement in serum 
creatinine with regard to initial 
values 
 Reduction of proteinuria of >50% 
(and at least <3 g/24 hours) 
 Plus sCr within 125% of the 
baseline value at 6 to 12 months 
after the start of the induction 
therapy 
Moderate response 
 At least 50% improvement in 2 
core renal parameters (with max 
uPCR ≤1000 mg/g) without 
clinically relevant worsening of 
the remaining renal core 
parameter  
Mild response 
 30–50% improvement in 2 core 
renal parameters without 
clinically relevant worsening of 
the remaining renal core 
parameter 
Renal core parameters: proteinuria 
(uPCR), renal function (creatinine 
clearance or sCr) and urine sediment 
(WBCs, RBCs, and casts) 
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Flare Nephritic flare 
 Reproducible increase 
of serum creatinine by 
≥30% (or, decrease in 
GFR by ≥10%)  
 Plus active urine 
sediment with 
increase in glomerular 
haematuria by ≥10 
RBCs/HPF 
 Irrespective of changes 
in proteinuria 
Proteinuric flare 
 Reproducible doubling 
of uPCR to >100 
mg/mmol after 
complete response 
 Or reproducible 
doubling of uPCR to 
>200 mg/mmol after 
partial response 
Mild kidney relapse 
 ↑ glomerular haematuria 
from <5 to >15 RBC/hpf, 
with ≥ 2 acanthocytes/HPF 
 And/or recurrence of ≥1 
RBC cast, WBC cast (no 
infection), or both 
Moderate kidney relapse 
 If baseline sCr is: 
 <2 mg/dl [<177 mmol/l]; 
increase of 0.2–1.0 mg/dl 
[17.7–88.4 mmol/l] 
 ≥2 mg/dl [≥177 mmol/l]; 
increase of 0.4–1.5 mg/dl 
[35.4–132.6 mmol/l] 
 And/or if baseline uPCR is: 
 <500 mg/g; increase to 
≥1000 mg/g 
 500–1000 mg/g; increase 
to ≥2000 mg/g, but less 
than absolute increase of 
<5000 mg/g 
 >1000 mg/g; increase of 
≥2-fold with absolute 
uPCR <5000 mg/g 
Severe kidney relapse  
 If baseline sCr is: 
 <2 mg/dl [<177 mmol/l]; 
increase of >1.0 mg/dl 
[>88.4 mmol/l] 
 ≥2 mg/dl [≥177 mmol/l]; 
increase of >1.5 mg/dl 
[>132.6 mmol/l] 
 and/or an absolute 
increase of uPCR >5000 
mg/g 
Mild recurrence 
 ↑ RBCs in sediment from <5 to 
>15/HPF with ≥2 dimorphic 
RBCs/HPF  
 And/or ≥1 cast, leukocyte count 
(in the absence of urinary 
infection), or both 
Moderate recurrence 
 If baseline sCr is: 
 <2 mg/dl, ↑ by 0.2-1 mg/dl 
 >2 mg/dl, ↑ by 0.4-1.5 mg/dl 
 And/or if the uPCR is: 
 <500 mg/g , ↑ by ≥1000 mg/g 
 500-1000 mg/g, ↑ by ≥2000 
mg/g 
 But with an absolute increase < 
5000 mg/g 
Severe recurrence 
 If baseline sCr is: 
 <2 mg/dl, ↑ by >1 mg/dl 
 ≥2 mg/dl, ↑ by >1.5 mg/dl 
 And/or a uPCR >5000 mg/g 
 
NB: in case of relapse rule out non-
compliance. 
 An increase in disease activity that 
requires intensification of the 
therapy, defined as:  
 An increase of ≥25% in the lowest 
sCr measured during the period of 
induction therapy  
 And/or the development of either 
a nephrotic syndrome (proteinuria 
>3.5 g/24 hours and serum 
albumin <30 g/l), while the lowest 
protein excretion so far has been 
≤2.0 g/24 hours repeatedly, or 
proteinuria >1.5 g/24 hours in a 
previous non-proteinuric patient 
Nephritic renal flare 
 Increase or recurrence of active 
urinary sediment (increased 
haematuria with or without 
reappearance of cellular casts)  
 With or without a concomitant 
increase in proteinuria 
Proteinuric/nephrotic renal flare 
 A persistent increase in uPCR 
>500 mg/g after achieving 
complete response  
 Or a doubling of proteinuria 
with uPCR >1000 mg/g, after 
achieving a partial response 
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Refractory 
disease 
 Failing to improve 
within 3–4 months 
 No partial response 
after 6–12 months of 
treatment  
 No complete response 
after 2 years of 
treatment 
No consensus definition Resistance to treatment is defined as 
an absence of complete or partial 
response after completing the 
induction therapy phase. But there is 
no consensus on how to define the 
minimum time for the induction 
therapy phase or the minimum 
cumulative dose of 
immunosuppressive drugs needed to 
consider the disease resistant to 
treatment 
DWP: Persistent or worsening renal disease activity as manifested by 
progressive deterioration of renal function and/or proteinuria despite optimal 
immunosuppressive therapy and supportive treatment, and involving at least 
one of the following conditions: 
I) failure of the initial induction treatment at three months, for which a switch 
to another induction therapy regime has already been carried out; II) 
intolerance for CYC and MMF; III) exceeding a cumulative dose of 15 gram of 
cyclophosphamide, IV) a second relapse within two years after start of the initial 
induction therapy, and V) a relative contraindication for high-dose oral or 
intravenous (iv) prednisone, such as avascular osteonecrosis, previous psychosis 
on corticosteroids, osteoporosis and/or severe obesity (BMI ≥35 kg/m
2
) 
Table S2. Definitions of response to treatment and flares 
ACR: “Definitions of response, degree of response, flare, severity of flare, and remission vary significantly in the literature and depend on the starting point in each individual patient; therefore, an exact 
definition of these terms was not included in the scenarios. Identification of response, flare, and failure to respond were based on the experienced clinician’s opinion, and it is intended that the treating clinician 
make similar judgments in employment of the recommendations outlined here” 
uPCR 100 mg/mmol ≡ 1000 mg/g ≡ 1(g/g) ≈ 1 g/24 h[55] 
 Abbreviations: ACR=American College of Rheumatology; CARRA=Childhood Arthritis and Rheumatology Research Alliance; DWP=Dutch Working Party on Systemic Lupus Erythematosus; EULAR/ERA-
EDTA=European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association; GEAS= Systemic auto-immune disease group of the Spanish Society of Internal 
Medicine and Spanish Society of Nephrology; GFR=glomerular filtration rate; HPF=high power field; KDIGO= Kidney Disease: Improving Global Outcomes Glomerulonephritis Work Group; RBC=red blood cell; 
sCr=serum creatinine; uPCR=urine protein-creatinine ratio. 
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EULAR/ERA-EDTA : European League Against Rheumatism and European Renal Association- European Dialysis and Transplant Association 
Level of evidence Diagnosis/Monitoring/Prognosis Treatment 
1 The available evidence is strong and includes consistent results from well-designed, well 
–conducted studies 
Meta-analysis of randomised controlled trial (RCT) or >1 RCTs 
2 The available evidence is sufficient to determine effects, but confidence in the estimate 
is constrained by such factors as: the number, size, or quality of individual studies, 
inconsistency of findings across individual studies, limited generalizability of findings 
Single RCT; long-term follow-up study of primary/secondary outcomes or post-hoc 
analysis based on the original randomization allocation 
3 The available evidence is weak due to the limited number or size of studies, important 
flaws in study design or methods, inconsistency of findings across individual studies, 
gaps in the chain of evidence, lack of information on important outcomes 
Non-randomised controlled study (prospective or retrospective) 
4 - Uncontrolled studies (case series) 
Strength of statements 
A Based on level 1 evidence Based on level 1 or 2 evidence without concerns for the validity of the evidence 
B Based on level 2 evidence; or extrapolated recommendations from category 1 evidence Based on level 1 or 2 evidence but with concerns about the validity of the evidence; 
or level 3 evidence without major concerns about the validity of the evidence 
C Based on category 3; or extrapolated recommendations from category 2 evidence; or 
no data (expert opinion); or extrapolation from non-SLE literature 
Based on level 3 evidence with concerns about the validity of the evidence; or level 
4 evidence; or no data (expert opinion); or extrapolation from non-SLE literature 
ACR/DWP: American College of Rheumatology/Dutch Working Party on SLE 
A Evidence represents data derived from multiple randomised controlled trials (RCTs) or meta-analysis 
B Evidence from a single RCT or non-randomised study 
C Evidence from consensus, expert opinion or case series 
KDIGO: Kidney Disease: Improving Global Outcomes Glomerulonephritis Work Group 
Strength of recommendation Patients Clinicians Policy 
1 (recommend) Most people in your situation would want the 
recommended course of action and only a small 
proportion would not 
Most patients should receive the recommended course of 
action 
The commendation can be evaluated as a candidate 
for developing a policy or performance measure 
2 (suggest) The majority of people in your situation would want 
the recommended course of action, but many would 
not 
Different choices will be appropriate for different patients; 
each patient needs help to arrive at a management decision 
consistent with her or his values and preferences 
The recommendation is likely to require substantial 
debate and involvement of stakeholders before 
policy can be determined 
Grade Quality of evidence Meaning 
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A High We are confident that the true effect lies close to that of the estimate of the effect 
B Moderate The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
C Low The true effect may be substantially different from the estimate of the effect 
D Very low The estimate of effect is very uncertain, and often will be far from the truth 
GEAS: Systemic auto-immune disease group of the Spanish Society of Internal Medicine and the Spanish Society of Nephrology 
Quality level of evidence 
A High 
B Moderate 
C Low 
D Very low 
Recommendations grade 
1 Strong 
2 Weak 
NG Not graded 
CARRA: Childhood Arthritis and Rheumatology Research Alliance 
A Supported by randomised clinical trials (RCTs) 
B Supported by non-randomised controlled studies or extrapolations from RCTs 
C Supported by uncontrolled studies, extrapolations from non-randomised controlled studies, or marked extrapolation from RCTs (e.g. adults to paediatrics) 
D Based on expert opinion 
Table S3. Quality of evidence and strength of recommendations as applied by the different guidelines 
 
